A Single Microneedle Patch Could Deliver a Month's Worth of Semaglutide Without Any Injections | Research

The takeaway

A programmable microneedle patch system delivers semaglutide in four timed-release bursts over one month from a single skin application, potentially replacing weekly injections with one painless patch.

1 patch = 4 weekly doses
Single-application microneedle patch replaces one month of semaglutide injections through programmed sequential release

What the researchers found

A single-application microneedle patch with 4 programmable core-shell pixels achieves sequential weekly semaglutide release over one month, simulating 4 separate bolus injections from one painless skin application.

Why it matters

Needle phobia and injection burden are major barriers to GLP-1 drug adherence. A painless, single-application monthly patch could dramatically improve patient compliance and make obesity treatment more accessible, while also reducing medical waste and the need for healthcare facilities.

The numbers in context

Semaglutide has a half-life of approximately 7 days. The patch system delivers multiple programmed doses from a single application.

How the study worked

Preclinical development of a programmable scheduled release microneedle (PSR-MN) system. Each 2cm × 2cm patch contains 4 pixel units (1cm² each) with core-shell architecture enabling time-programmed drug release at 7-day intervals.

Who was studied

Preclinical testing (not human subjects)

What this study cannot tell us

Preclinical stage — no human trials reported. The precise release kinetics in human skin may differ from lab testing. Scalability and manufacturing costs are not addressed. Skin reactions to the patch over a month of wear are not characterized. Storage stability of the patch needs validation.

How to read the evidence

Preliminary evidence from preclinical development. Proof-of-concept for the delivery technology but no human pharmacokinetic or efficacy data yet.

When this study was published

Published in 2024. Represents cutting-edge drug delivery technology for peptide therapeutics.

The bigger picture

Drug delivery innovation is key to maximizing the impact of effective medications. As GLP-1 drugs transform obesity treatment, making them easier and less painful to use could expand access to millions more patients worldwide, particularly in settings without regular access to healthcare providers for injections.

Questions still open

How does the pharmacokinetic profile of patch delivery compare to subcutaneous injection in clinical settings?
Can the patch maintain therapeutic drug levels as reliably as injections?
What are the manufacturing costs and scalability challenges for this technology?

Common questions

How do microneedle patches work?

Microneedle patches have tiny, dissolving needles on their surface — small enough to penetrate only the outermost skin layer without reaching pain-sensing nerves. The drug is contained within these needles or in reservoirs beneath them, and it's released into the skin as the needles dissolve.

When could this be available?

This technology is still in early development. It would need to go through human clinical trials to prove it delivers semaglutide as effectively as injection and to verify safety. This process typically takes several years.

Read the original research

Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.

Advanced therapeutics, 7(9)

View on PubMed ↗Publisher’s paper ↗

Citation

Singh, Parbeen; Vinikoor, Tra; Sharma, Nidhi; Nelson, Nicole; Prasadh, Somasundaram; Oiknine, Ralph; Nguyen, Thanh Duc. (2024). Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.. Advanced therapeutics, 7(9). https://doi.org/10.1002/adtp.202400028